Amiloidosis de Inmunoglobulinas: Diagnóstico, Tratamiento y Fisicoquímica
Resumen
Las amiloidosis de inmunoglobulinas son enfermedades ocasionadas por los fragmentos insolubles de las inmunoglobulinas que se depositan en diversos tejidos formando fibras amiloides; esta acumulación anormal de proteínas produce disfunción orgánica y eventualmente la muerte. Esta patología se divide en 2 tipos: la amiloidosis AL y la amiloidosis AH, la primera es la forma sistémica más frecuente, donde los amiloides derivan de fragmentos de las cadenas ligeras de las inmunoglobulinas; la segunda es menos frecuente y resulta de la deposición de fragmentos de las cadenas pesadas. Determinar si son fragmentos de la cadena ligera o pesada es importante para el pronóstico y el tratamiento. En esta revisión se abordan los procesos termodinámicos y cinéticos que conducen a la agregación de estas proteínas así como las patologías, sus diagnósticos y tratamientos.
Descargas
Citas
Tanskanen M. “Amyloid” — Historical Aspects. In: Amyloidosis. InTech; 2013.
Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: A summary of progress over the last decade. Annu Rev Biochem. 2017;86:27–68.
Iadanza MG, Jackson MP, Hewitt EW, Ranson NA, Radford SE. A new era for understanding amyloid structures and disease. Nat Rev Mol Cell Biol. 2018;19(12):755–73.
Strohl WR, Strohl LM. Therapeutic antibody engineering: current and future advances driving the strongest growth area in the pharmaceutical industry. Elsevier. 2012.
Delves PJ, Martin SJ, Burton DR, Roitt IM. Roitt’s essential immunology. John Wiley & Sons; 2017.
Berner N, Reutter K-R, Wolf DH. Protein quality control of the endoplasmic reticulum and ubiquitin-proteasome-triggered degradation of aberrant proteins: Yeast pioneers the path. Annu Rev Biochem. 2018;87:751–82.
Manabe S, Hatano M, Yazaki M, Nitta K, Nagata M. Renal AH amyloidosis associated with a truncated immunoglobulin heavy chain undetectable by immunostaining. Am J Kidney Dis. 2015;66(6):1095–100.
D’Aguanno V, Ralli M, Artico M, Russo FY, Scarpa A, Fiore M, et al. Systemic amyloidosis: A contemporary overview. Clin Rev Allergy Immunol. 2020;59(3):304–22.
Papathanasiou M, Carpinteiro A, Rischpler C, Hagenacker T, Rassaf T, Luedike P. Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist. Int J Cardiol Heart Vasc. 2020;28(100519):100519.
Mahmood S, Palladini G, Sanchorawala V, Wechalekar A. Update on treatment of light chain amyloidosis. haematologica. Vol. Feb;99(2):209. 2014.
Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.
Hekmatimoghaddam S, Zare-Khormizi MR, Pourrajab F. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases: Chemical/biochemical therapeutic approaches to ameliorate PMND. Biofactors. 2017;43(6):737–59.
Kundu D, Prerna K, Chaurasia R, Bharty MK, Dubey VK. Advances in protein misfolding, amyloidosis and its correlation with human diseases. 3 Biotech. 2020;10(5):193.
Wu H-T, Wen Y-B, Ye W, Liu B-Y, Shen K-N, Gao R-T, et al. Underlying IgM heavy chain amyloidosis in treatment-refractory IgA nephropathy: A case report. World J Clin Cases. 2019;7(19):3055–61.
Kourelis TV, Dasari S, Theis JD, Ramirez-Alvarado M, Kurtin PJ, Gertz MA, et al. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017;129(3):299–306.
Varga C, Titus SE, Toskic D, Comenzo RL. Use of novel therapies in the treatment of light chain amyloidosis. Blood Rev. 2019;37(100581):100581.
Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017;103(14):1065–72.
Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review. J Autoimmun. 2015;57:1–13.
Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160–71.
Rodwell VW, Bender D, Botham KM, Kennelly PJ, Weil PA. Harper’s Illustrated Biochemistry 31/e. 31st ed. Columbus, OH: McGraw-Hill Education; 2018.
Casadevall A, Janda A. Immunoglobulin isotype influences affinity and specificity. Proceedings of the national academy of sciences. 2012 Jul 31;109(31):12272-3.
Altrichter S, Zampeli V, Ellrich A, Zhang K, Church MK, Maurer M. IgM and IgA in addition to IgG autoantibodies against FcɛRIα are frequent and associated with disease markers of chronic spontaneous urticaria. Allergy. 2020 Dec;75(12):3208-15.
Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, Function, and Therapeutic Use of IgM Antibodies. Antibodies. 2020 Dec;9(4):53.
Tomasello G, Armenia I, Molla G. The Protein Imager: a full-featured online molecular viewer interface with server-side HQ-rendering capabilities. Bioinformatics. 2020 May 1;36(9):2909-11.
Pauling L, Corey RB, Branson HR. The structure of proteins: two hydrogen-bonded helical configurations of the polypeptide chain. Proceedings of the National Academy of Sciences. 1951 Apr 1;37(4):205-11.
Watson JD, Crick FH. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature. 1953 Apr;171(4356):737-8.
Kendrew JC, Bodo G, Dintzis HM, Parrish RG, Wyckoff H, Phillips DC. A three-dimensional model of the myoglobin molecule obtained by x-ray analysis. Nature. 1958 Mar;181(4610):662-6.
Muirhead H, Perutz MF. Structure of hæemoglobin: A three-dimensional fourier synthesis of reduced human haemoglobin at 5.5 Å resolution. Nature. 1963 Aug;199(4894):633-8.
Miti T, Mulaj M, Schmit JD, Muschol M. Stable, metastable, and kinetically trapped amyloid aggregate phases. Biomacromolecules. 2015 Jan 12;16(1):326-35.
Chuang E, Hori AM, Hesketh CD, Shorter J. Amyloid assembly and disassembly. Journal of Cell Science. 2018 Apr 15;131(8).
Lutter L, Serpell CJ, Tuite MF, Xue WF. The molecular lifecycle of amyloid–Mechanism of assembly, mesoscopic organisation, polymorphism, suprastructures, and biological consequences. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics. 2019 Nov 1;1867(11):140257.
Ke PC, Zhou R, Serpell LC, Riek R, Knowles TP, Lashuel HA, Gazit E, Hamley IW, Davis TP, Fändrich M, Otzen DE. Half a century of amyloids: past, present and future. Chemical Society Reviews. 2020;49(15):5473-509.
Colon W, Church J, Sen J, Thibeault J, Trasatti H, Xia K. Biological roles of protein kinetic stability. Biochemistry. 2017 Nov 28;56(47):6179-86.
Matiiv AB, Trubitsina NP, Matveenko AG, Barbitoff YA, Zhouravleva GA, Bondarev SA. Amyloid and Amyloid-Like Aggregates: Diversity and the Term Crisis. Biochemistry (Moscow). 2020 Sep;85(9):1011-34.
Almeida ZL, Brito RMM. Structure and aggregation mechanisms in amyloids. Molecules. 2020;25(5):1195.
Sasahara K, Yamaguchi K, So M, Goto Y. Polyphosphates diminish solubility of a globular protein and thereby promote amyloid aggregation. J Biol Chem. 2019;294(42):15318–29.
Blancas-Mejía LM, Misra P, Ramirez-Alvarado M. Differences in protein concentration dependence for nucleation and elongation in light chain amyloid formation. Biochemistry. 2017;56(5):757–66.
Arosio P, Knowles TPJ, Linse S. On the lag phase in amyloid fibril formation. Phys Chem Chem Phys. 2015;17(12):7606–18.
Buell AK. The growth of amyloid fibrils: rates and mechanisms. Biochem J. 2019;476(19):2677–703
Marin-Argany M, Lin Y, Misra P, Williams A, Wall JS, Howell KG, et al. Cell damage in light chain amyloidosis: Fibril internalization, toxicity and cell-mediated seeding. J Biol Chem. 2016;291(38):19813–25.
Buell AK. The nucleation of protein aggregates - from crystals to amyloid fibrils. Int Rev Cell Mol Biol. 2017;329:187–226.
Lermyte F. Roles, characteristics, and analysis of intrinsically disordered proteins: A minireview. Life (Basel). 2020;10(12):320.
Baldwin AJ, Knowles TPJ, Tartaglia GG, Fitzpatrick AW, Devlin GL, Shammas SL, et al. Metastability of native proteins and the phenomenon of amyloid formation. J Am Chem Soc. 2011;133(36):14160–3.
Muntau AC, Leandro J, Staudigl M, Mayer F, Gersting SW. Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J Inherit Metab Dis. 2014;37(4):505–23
Carballo-Pacheco M, Ismail AE, Strodel B. Oligomer formation of toxic and functional amyloid peptides studied with atomistic simulations. J Phys Chem B. 2015;119(30):9696–705.
Sulatsky MI, Sulatskaya AI, Stepanenko OV, Povarova OI, Kuznetsova IM, Turoverov KK. Denaturant effect on amyloid fibrils: Declasterization, depolymerization, denaturation and reassembly. Int J Biol Macromol. 2020;150:681–94.
Crespo R, Villar-Alvarez E, Taboada P, Rocha FA, Damas AM, Martins PM. What can the kinetics of amyloid fibril formation tell about off-pathway aggregation? J Biol Chem. 2016;291(4):2018–32.
Hall D, Kardos J, Edskes H, Carver JA, Goto Y. A multi-pathway perspective on protein aggregation: Implications for control of the rate and extent of amyloid formation. FEBS Lett. 2015;589(6):672–9.
Vettore N, Buell AK. Thermodynamics of amyloid fibril formation from chemical depolymerization. Phys Chem Chem Phys. 2019;21(47):26184–94.
Gillmore JD, Wechalekar A, Bird J, Cavenagh J, Hawkins S, Kazmi M, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol. 2015;168(2):207–18.
González-Andrade M, Becerril-Luján B, Sánchez-López R, Ceceña-Álvarez H, Pérez-Carreón JI, Ortiz E, et al. Mutational and genetic determinants of λ6 light chain amyloidogenesis. FEBS J. 2013;280(23):6173–83.
Radamaker L, Lin Y-H, Annamalai K, Huhn S, Hegenbart U, Schönland SO, et al. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. Nat Commun. 2019;10(1):1103.
Menè P, De Alexandris L, Moioli A, Raffa S, Stoppacciaro A. Monoclonal Gammopathies of Renal Significance: Renal biopsy and beyond. Cancers (Basel). 2020;12(7):1741.
Komatsuda A, Ohtani H, Sawada K, Joh K, Wakui H. Proliferative glomerulonephritis with discrete deposition of monoclonal immunoglobulin γ1 CH2 heavy chain and κ light chain: a new variant of monoclonal immunoglobulin deposition disease: A new variant of MIDD. Pathol Int. 2013;63(1):63–7.
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641–54.
Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046–53.
González-López E, Gagliardi C, Dominguez F, Quarta CC, de Haro-del Moral FJ, Milandri A, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38(24):1895–904.
Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, et al. Comparative analysis of staging systems in AL amyloidosis. Leukemia. 2019;33(3):811–4.
Krsnik I, Cabero M, Morillo D, Segovia J, García-Pavía P, Gómez-Bueno M, et al. Light chain amyloidosis: Experience in a tertiary hospital: 2005–2013. Rev Clin Esp (Barc). 2015;215(1):1–8.
Di Bella G, Pizzino F, Minutoli F, Zito C, Donato R, Dattilo G, et al. The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. Eur Heart J Cardiovasc Imaging. 2014;15(12):1307–15.
Gertz MA. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment: GERTZ. Am J Hematol. 2018;93(9):1169–80.
Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment. Am J Hematol. 2020;95(7):848–60.
Yakupova EI, Bobyleva LG, Vikhlyantsev IM, Bobylev AG. Congo Red and amyloids: history and relationship. Biosci Rep. 2019;39(1):BSR20181415.
Milani P, Palladini G, Merlini G. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions. Scand J Clin Lab Invest Suppl. 2016;245(sup245):S113-8.
Aoki M, Kang D, Katayama A, Kuwahara N, Nagasaka S, Endo Y, et al. Optimal conditions and the advantages of using laser microdissection and liquid chromatography tandem mass spectrometry for diagnosing renal amyloidosis. Clin Exp Nephrol. 2018;22(4):871–80.
Al Saleh AS, Sidiqi MH, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, et al. Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(8):1402–5.
Singer S, Efebera Y, Bumma N, Khan A, Devarakonda S, Chaudhry M, et al. Heavy lifting: Nomenclature and novel therapy for gamma heavy chain disease and other heavy chain disorders. Clin Lymphoma Myeloma Leuk. 2020;20(8):493–8.
Nasr SH, Said SM, Valeri AM, Sethi S, Fidler ME, Cornell LD, et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int. 2013;83(3):463–70.
Martin EB, Williams A, Wooliver C, Heidel RE, Adams S, Dunlap J, et al. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity. PLoS One. 2017;12(3):e0174152.
Pradhan MA, Henderson RA, Patel D, McGhee CNJ, Vincent AL. Heavy-chain amyloidosis in TGFBI-negative and gelsolin-negative atypical lattice corneal dystrophy. Cornea. 2011;30(10):1163–6.
Sethi S, Rajkumar SV, D’Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol. 2018;29(7):1810–23.
Fu J, Lee LX, Zhou P, Fogaren T, Varga C, Comenzo RL. A case of T-cell large granular Lymphocytic leukemia and renal immunoglobulin heavy chain amyloidosis. Am J Case Rep. 2019;20:43–7.
Dittrich T, Kimmich C, Hegenbart U, Schönland SO. Prognosis and staging of AL amyloidosis. Acta Haematol. 2020;143(4):388–400.
Picken MM. Monoclonal Gammopathies: Glomerular and Tubular Injuries. In: Pathobiology of Human Disease. Elsevier; 2014. p. 2831–52.
Budd RC, Seldin DC. Amyloidosis. In: Kelley and Firestein’s Textbook of Rheumatology. Elsevier; 2017. p. 1973–82.
Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021;289(3):268–92.
Blancas-Mejía LM, Martin EB, Williams A, Wall JS, Ramirez-Alvarado M. Kinetic stability and sequence/structure studies of urine-derived Bence-Jones proteins from multiple myeloma and light chain amyloidosis patients. Biophys Chem. 2017;230:89–98.
Derechos de autor 2023 Miguel Alejandro Rodríguez López , Julian Grandvallet Contreras, Edgar Vázquez Contreras
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.jpg)
